| Literature DB >> 34943749 |
Yoshiro Sakai1,2,3, Kenji Gotoh2,3, Ryuichi Nakano4, Jun Iwahashi2, Miho Miura3, Rie Horita5, Naoki Miyamoto5, Hisakazu Yano4, Mikinori Kannae6, Osamu Takasu6, Hiroshi Watanabe2,3.
Abstract
BACKGROUND: A carbapenem-resistant Enterobacteriaceae (CRE) outbreak occurred in an advanced emergency medical service center [hereafter referred to as the intensive care unit (ICU)] between 2016 and 2017. AIM: Our objective was to evaluate the infection control measures for CRE outbreaks.Entities:
Keywords: carbapenem-resistant Enterobacteriaceae (CRE); carbapenemase; infection control; multilocus sequence typing (MLST); outbreak; pulsed-field gel electrophoresis (PFGE)
Year: 2021 PMID: 34943749 PMCID: PMC8698558 DOI: 10.3390/antibiotics10121537
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1The time course for a CRE outbreak in the ICU. Gray shadow: period of hospitalization. Black circle: the first day of CRE strain detection.
Antibiotics susceptibolity profiles (minimum inhibitory concentrations, mg/L).
| Patient No. | ABPC | PIPC | CTX | CAZ | CFPM | CMZ | IPM | MEPM | AZT | ABPC/SBT | PIPC/TAZ | GM | AMK | MINO | LVFX | ST |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | >16 | <8 | >2 | >8 | 4 | >32 | 2 | >2 | <4 | >16 | <16 | 4 | <4 | 4 | 2 | <2 |
| 2 | >16 | >64 | >2 | >8 | >16 | >32 | >2 | >2 | <4 | >16 | 64 | >8 | <4 | 4 | 1 | <2 |
| 3 | >16 | >64 | >2 | >8 | >16 | >32 | >2 | >2 | <4 | >16 | >64 | >8 | <4 | 4 | 1 | <2 |
| 4 | >16 | <8 | <1 | <4 | <2 | >32 | 2 | <1 | <4 | 16 | <16 | <2 | <4 | 4 | <0.5 | <2 |
| 5 | >16 | >64 | >2 | >8 | >16 | >32 | >2 | >2 | >8 | >16 | >64 | 8 | <4 | <2 | <0.5 | <2 |
| 6 | <8 | <8 | <1 | <4 | <2 | >32 | 2 | <1 | <4 | <8 | <16 | <2 | <4 | <2 | <0.5 | <2 |
| 7 | >16 | <8 | <1 | <4 | <2 | >32 | 2 | <1 | <4 | 16 | <16 | <2 | <4 | <2 | <0.5 | <2 |
| 8 | >16 | >64 | >2 | >8 | >16 | >32 | >2 | >2 | >8 | >16 | >64 | >8 | <4 | >8 | 4 | <2 |
| 9 | >16 | >64 | >2 | >8 | >16 | >32 | >2 | >2 | <4 | >16 | 64 | >8 | <4 | >8 | 4 | >2 |
| 10 | >16 | 16 | >2 | >8 | >16 | >32 | 2 | >2 | <4 | >16 | <16 | 8 | <4 | 4 | 4 | >2 |
| 11 | >16 | <8 | <1 | <4 | <2 | >32 | 2 | <1 | <4 | 16 | <16 | <2 | <4 | <2 | <0.5 | <2 |
| 12 | >16 | <8 | >2 | >8 | 4 | >32 | >2 | >2 | <4 | >16 | <16 | >8 | <4 | <2 | 1 | <2 |
| 13 | >16 | <8 | 2 | <4 | <2 | >32 | 2 | <1 | <4 | >16 | <16 | <2 | <4 | 4 | <0.5 | <2 |
| 14 | >16 | <8 | <1 | <4 | <2 | >32 | 2 | <1 | <4 | 16 | <16 | <2 | <4 | <2 | <0.5 | <2 |
| 15 | >16 | <8 | >2 | <4 | <2 | >32 | 2 | <1 | <4 | >16 | <16 | <2 | <4 | <2 | <0.5 | <2 |
| 16 | >16 | <8 | <1 | <4 | <2 | >32 | 2 | <1 | <4 | 16 | <16 | <2 | <4 | <2 | <0.5 | <2 |
ABPC: ampicillin, PIPC: piperacillin, CTX: cefotaxime, CAZ: ceftazidime, CFPM: cefepime, CMZ: cefmetazole, IPM: imipenem, MEPM: meropenem, AZT: aztreonam, ABPC/SBT: ampicillin/sulbactam, PIPC/TAZ: piperacillin/tazobactam, GM: gentamicin, AMK: amikacin, MINO: minocycline, LVFX: levofloxacin, ST: sulfamethoxazole-trimethoprim.
Figure 2PFGE patterns of XbaI-digested DNA from 25 CRE isolates (22 from inpatients and 3 from environments). Molecular typing showed that the PFGE patterns of 25 CRE isolates were divided into eight patterns (A–I). Those of K. pneumoniae in strains three and four, E. asburiae from strains 5 to 16, and E. cloacae strains from strains No.19 to 22 were closely related. Similarly, the MLST patterns of 2 K. pneumoniae in strains three and four were identical as ST2388 and those of four E. cloacae strains from strains 19 to 22 were identical as ST252.
Distribution of β-lactamase genes for 25 CRE isolates (22 from inpatients and 3 from environments). Twenty-three isolates were positive for CIM and all of the isolates harbored the IMP-1 β-lactamase gene. Two other CIM-negative isolates harbored no carbapenemase gene. Incompatibility group typing revealed two types of plasmids in the CPEs. Fifteen of the 23 CPE isolates possessed IncFIIA replicon regions, including K. pneumoniae (n = 2), E. asburiae (n = 11), and E. cloacae (n = 2). Two other isolates belonged to IncN in K. pneumoniae, and the Inc type could not be determined for the six remaining isolates.
| Strain No. | Carbapenemase | CTX-M | ESBL | CIM | Inc |
|---|---|---|---|---|---|
| 1 | IMP-1 | ND | SHV | + | FIIA |
| 2 | IMP-1 | ND | SHV | + | FIIA |
| 3 | IMP-1 | ND | SHV | + | N |
| 4 | IMP-1 | ND | SHV | + | N |
| 5 | IMP-1 | ND | ND | + | FIIA |
| 6 | IMP-1 | ND | TEM, SHV | + | FIIA |
| 7 | IMP-1 | ND | TEM, SHV | + | FIIA |
| 8 | IMP-1 | ND | ND | + | FIIA |
| 9 | IMP-1 | ND | SHV | + | ND |
| 10 | IMP-1 | ND | TEM, SHV | + | FIIA |
| 11 | IMP-1 | ND | ND | + | FIIA |
| 12 | IMP-1 | ND | ND | + | FIIA |
| 13 | IMP-1 | ND | ND | + | FIIA |
| 14 | IMP-1 | ND | ND | + | FIIA |
| 15 | IMP-1 | ND | ND | + | FIIA |
| 16 | IMP-1 | ND | ND | + | FIIA |
| 17 | IMP-1 | ND | ND | + | ND |
| 18 | IMP-1 | ND | ND | + | ND |
| 19 | IMP-1 | ND | TEM, SHV | + | ND |
| 20 | IMP-1 | ND | TEM | + | ND |
| 21 | IMP-1 | ND | TEM, SHV | + | FIIA |
| 22 | IMP-1 | ND | TEM, SHV | + | FIIA |
| 23 | ND | ND | ND | - | ND |
| 24 | IMP-1 | ND | TEM | + | ND |
| 25 | ND | ND | ND | - | FIIA |
EBSL: extended-spectrum β-lactamase, CIM: Carbapenem Inactivation Method, ND: not deceted.